Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin (2016 - 2025)

Historic EBT Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to 66.42%.

  • Vanda Pharmaceuticals' EBT Margin fell 542000.0% to 66.42% in Q4 2025 from the same period last year, while for Dec 2025 it was 64.16%, marking a year-over-year decrease of 526300.0%. This contributed to the annual value of 64.16% for FY2025, which is 526300.0% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its EBT Margin stood at 66.42% for Q4 2025, which was down 542000.0% from 50.46% recorded in Q3 2025.
  • Vanda Pharmaceuticals' EBT Margin's 5-year high stood at 18.56% during Q2 2021, with a 5-year trough of 74.67% in Q1 2025.
  • Moreover, its 5-year median value for EBT Margin was 1.99% (2023), whereas its average is 10.69%.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' EBT Margin soared by 214100bps in 2023, and later plummeted by -648500bps in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' EBT Margin (Quarter) stood at 12.66% in 2021, then grew by 18bps to 14.91% in 2022, then tumbled by -125bps to 3.67% in 2023, then plummeted by -233bps to 12.22% in 2024, then plummeted by -444bps to 66.42% in 2025.
  • Its last three reported values are 66.42% in Q4 2025, 50.46% for Q3 2025, and 66.34% during Q2 2025.